Ranbaxy definition

Ranbaxy means: Ranbaxy Laboratories Ltd., its directors, officers, employees, agents, representatives, successors, and assigns; and its joint ventures, subsidiaries, divisions, groups and affiliates in each case controlled by Ranbaxy Laboratories Ltd. (including, without limitation, Ohm Laboratories, Inc.), and the respective directors, officers, employees, agents, representatives, successors, and assigns of each.

Split View

AI-Powered Contracts

Draft, Review & Redline at the Speed of AI

Get StartedSchedule a Demo

Ranbaxy means, collectively, Ranbaxy Inc., Ranbaxy Laboratories Limited, and Ranbaxy Pharmaceuticals, Inc. Ranbaxy and Pfizer are collectively referred to as “Defendants.” The proposed Settlement is with Pfizer only.

Ranbaxy means RANBAXY LABORATORIES LIMITED, a corporation existing and operating under the laws of India with principal place of business at ▇▇▇▇ ▇▇, **Portions of the Exhibit have been omitted and have been filed separately purusant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. ▇▇▇▇▇▇ ▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇▇ (▇▇▇▇▇▇▇), ▇▇▇▇▇, and its directors, officers, employees, agents and representatives, predecessors, successors, and assigns; its subsidiaries, divisions, groups, and the respective directors, officers, employees, agents and representatives, successors, and assigns of each.

Examples of Ranbaxy in a sentence

• Ranbaxy may contract with Third Parties for the distribution of the Licensed Products pursuant to the exercise of the co-marketing rights provided herein.

• Class Members shall look solely to the Settlement Fund for settlement and satisfaction against Ranbaxy of all claims that are released hereunder.

• Ranbaxy and Plaintiffs shall each have the option to terminate the Settlement and have the Settlement Payment refunded to Ranbaxy if the Court declines to grant final approval to the Settlement.

• On March 25, 2004, Aventis and AMR filed a complaint and first amended complaint against the Company and Ranbaxy, alleging infringement of two additional patents relating to the process for making the active pharmaceutical ingredient, fexofenadine hydrochloride.

• Ohm Laboratories, Inc., incorporated in New Jersey; Ranbaxy Pharmaceuticals, Inc., incorporated in Florida; Ranbaxy Laboratories, Inc., incorporated in Delaware; and Ranbaxy USA, Inc., incorporated in Florida, are all subsidiaries of Ranbaxy, Inc.

• If, for any reason, for any period of time, Ranbaxy is required to pay taxes on income earned by the Settlement Fund, the Escrow Agent shall, upon written instructions from Ranbaxy with notice to Lead Class Counsel, timely issue payment from the Settlement Fund to enable the payment of all taxes (state, federal, or other, including to any foreign jurisdiction) on income earned by the Settlement Fund.

• At all relevant times, Ranbaxy distributed and sold in the United States pharmaceutical products that were manufactured at its facilities in Paonta Sahib, India, and Dewas, India (“Covered Drugs”).

• Ranbaxy, Inc., incorporated in Delaware, is the United States subsidiary of Ranbaxy Laboratories Limited.

• Ranbaxy shall have no responsibility whatsoever for the allocation or distribution of the Settlement Fund and shall not be responsible for disputes relating to the amount, allocation, or distribution of any fees or expenses.

• Ranbaxy Laboratories Limited is a public company incorporated under India law with headquarters in Gurgaon, India.

More Definitions of Ranbaxy

Ranbaxy includes defendants Ranbaxy Pharmaceuticals, Inc., Ranbaxy Inc., and Ranbaxy Laboratories Ltd. (collectively, “Ranbaxy”). “Teva” includes defendants Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA, Inc. (collectively, “Teva”). “▇▇. ▇▇▇▇▇’▇” includes defendants ▇▇. ▇▇▇▇▇’▇ Laboratories, Ltd. and ▇▇. ▇▇▇▇▇’▇ Laboratories, Inc. (collectively, “▇▇. ▇▇▇▇▇’▇”). Plaintiffs in the lawsuit claim that Defendants hurt competition and violated state laws in Arizona, California, Florida, Iowa, Kansas, Massachusetts, Maine, Michigan, Minnesota, Mississippi, Nebraska, Nevada, New Mexico, New York, North Carolina, North Dakota, Oregon, Rhode Island, South Dakota, Tennessee, Utah, Vermont, West Virginia, Wisconsin, and the District of Columbia by unlawfully delaying the availability of allegedly less expensive generic versions of Nexium. Plaintiffs allege that Defendants’ conduct caused certain consumers and third-party payors (discussed below) to pay too much for Nexium in these states. Defendants deny any wrongdoing. Settlements have been reached with ▇▇. ▇▇▇▇▇’▇ and Teva (collectively, “Settling Defendants”). The lawsuit will continue against the other Defendants (collectively, “Non-Settling Defendants”).